ENTA ENANTA PHARMACEUTICALS INC

Nasdaq enanta.com


$ 12.14 $ -0.23 (-1.86 %)    

Wednesday, 19-Nov-2025 15:47:33 EST
QQQ $ 608.64 $ 0.00 (0 %)
DIA $ 464.47 $ 0.00 (0 %)
SPY $ 670.28 $ 0.00 (0 %)
TLT $ 88.88 $ 0.00 (0 %)
GLD $ 373.82 $ 0.00 (0 %)
$ 12.13
$ 12.27
$ 12.13 x 68
$ 13.80 x 314
-- - --
$ 4.09 - $ 15.34
259,095
na
350.1M
$ 1.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-19-2025 09-30-2025 10-K
2 08-13-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 02-12-2025 12-31-2024 10-Q
5 11-27-2024 09-30-2024 10-K
6 08-07-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-08-2024 12-31-2023 10-Q
9 11-22-2023 09-30-2023 10-K
10 08-08-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 02-08-2023 12-31-2022 10-Q
13 11-23-2022 09-30-2022 10-K
14 08-08-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 02-10-2022 12-31-2021 10-Q
17 11-24-2021 09-30-2021 10-K
18 08-09-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 02-09-2021 12-31-2020 10-Q
21 11-25-2020 09-30-2020 10-K
22 08-10-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 02-10-2020 12-31-2019 10-Q
25 11-27-2019 09-30-2019 10-K
26 08-09-2019 06-30-2019 10-Q
27 05-10-2019 03-31-2019 10-Q
28 02-08-2019 12-31-2018 10-Q
29 11-29-2018 09-30-2018 10-K
30 08-09-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 02-09-2018 12-31-2017 10-Q
33 12-11-2017 09-30-2017 10-K
34 08-09-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 02-09-2017 12-31-2016 10-Q
37 12-09-2016 09-30-2016 10-K
38 08-09-2016 06-30-2016 10-Q
39 05-10-2016 03-31-2016 10-Q
40 02-09-2016 12-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 enanta-pharma-q4-eps-087-beats-103-estimate-sales-15125m-miss-15956m-estimate

Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(1.03)...

 jp-morgan-initiates-coverage-on-enanta-pharma-with-overweight-rating-announces-price-target-of-17

JP Morgan analyst Anupam Rama initiates coverage on Enanta Pharma (NASDAQ:ENTA) with a Overweight rating and announces Price...

 enanta-pharmaceuticals-highlights-promising-zelicapavir-pediatric-results-and-edp-323-post-exposure-prophylaxis-data-for-rsv-at-idweek-2025

Zelicapavir Results in Shortened Symptom Duration in Pediatric PatientsEDP-323 is Highly Effective in a Post-Exposure Prophylax...

 enanta-pharmaceuticals-to-showcase-rsv-drug-data-at-idweek-2025-highlighting-two-oral-once-daily-treatments

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule ...

 jefferies-upgrades-enanta-pharma-to-buy-raises-price-target-to-20

Jefferies analyst Akash Tewari upgrades Enanta Pharma (NASDAQ:ENTA) from Hold to Buy and raises the price target from $14 to...

 enanta-pharma-commences-50m-public-offering-with-option-to-sell-additional-75m-in-common-stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs f...

 westpark-capital-maintains-buy-on-enanta-pharma-raises-price-target-to-28

WestPark Capital analyst Ed Arce maintains Enanta Pharma (NASDAQ:ENTA) with a Buy and raises the price target from $24 to $28.

Core News & Articles

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and...

 enantas-rsv-pill-shows-promise-in-cutting-recovery-time-for-high-risk-adults

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) on Monday released topline data from RSVHR Phase 2b study of zelicapavir in outpati...

Core News & Articles

Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands...

 enanta-pharma-reports-topline-data-from-rsvhr-phase-2b-study-to-evaluate-efficacy-and-safety-of-zelicapavir-in-outpatient-adults-with-acute-rsv-infection

6.7-Day Improvement in Time to Complete Resolution of All RSV Symptoms for Patients with Chronic Obstructive Pulmonary Disease ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION